Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and PEGPH20 in Resectable Pancreatic Cancer
NCT03979066Phase 2Terminated
- Start
- Nov 2019
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegvorhyaluronidase alfa in pancreatic ductal adenocarcinoma (PDAC) (2 arms). Primary endpoint: Change in the Number of CD8+ T Cells Within the Tumor at 3 weeks. Started Nov 2019; status: terminated.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03979066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03979066.